Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2016-01-694604 http://scihub22266oqcxt.onion/10.1182/blood-2016-01-694604 C4900953!4900953!27091875     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood 2016 ; 127 (23): 2833-40 Nephropedia Template TP {{tp|p=27091875|t=2016. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM |pdf=|usr=}}{{27091875}} gab.com Text Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=27091875 #FOAvip Elotuzumab, an immunostimulatory antibody, prolongs PFS with no added clinical toxicity when combined with Bd vs Bd alone in RRMM.Based on results from this phase 2 study, further investigation of elotuzumab with a proteasome inhibitor in RRMM is warranted. Twit Text FOAVip Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=27091875 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27091875 #FOAvip English Wikipedia <ref>{{Cite pmid|27091875}}</ref> Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM #MMPMID27091875 Jakubowiak A; Offidani M; Pégourie B; De La Rubia J; Garderet L; Laribi K; Bosi A; Marasca R; Laubach J; Mohrbacher A; Carella AM; Singhal AK; Tsao LC; Lynch M; Bleickardt E; Jou YM; Robbins M; Palumbo A Blood 2016[Jun]; 127 (23): 2833-40 PMID27091875show ga Elotuzumab, an immunostimulatory antibody, prolongs PFS with no added clinical toxicity when combined with Bd vs Bd alone in RRMM.Based on results from this phase 2 study, further investigation of elotuzumab with a proteasome inhibitor in RRMM is warranted. äRandomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs (epmc).pdf DeepDyve Pubget Overpricing